CClinicalTrials.gg
CompletedNCT02454296Updated Apr 14, 2017Results posted

Paracervical Block for Pain Associated With Laminaria Insertion

An interventional study of Paracervical Block with lidocaine and Sham paracervical block in Pain, sponsored by University of Hawaii. Completed at 1 site in United States. Open to female participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-14.

Sponsored by University of Hawaii · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Study summary

To assess if paracervical block is effective at reducing discomfort during placement of intracervical laminaria for pre-operative cervical preparation.

Read the detailed description

Pre-operative dilation of the cervix with use of osmotic dilators (e.g. laminaria, dilapan-S) is commonly done prior to pregnancy termination to make the procedure safer. This study seeks to assess whether paracervical blocks are effective at reducing pain associated with placement of laminaria. Secondarily, this study will evaluate if paracervical blocks are effective at reducing overall procedural pain and increasing overall patient satisfaction for the intracervical laminaria placement procedure.

02

Conditions studied

  • Pain

Keywords

  • Laminaria
03

In context

Lead sponsor

University of Hawaii is the lead sponsor of 95 studies on the registry; 20 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Pregnant women between the ages of 18-49 years
  • Desiring surgical termination of pregnancy or surgical management of a fetal demise
  • Treatment plan involves cervical preparation with laminaria
  • Participant able to provide informed consent in English and willing to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Unable to read/speak/understand English
  • Contraindications to receiving lidocaine
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
41 participants (actual)

Study arms

  • Active comparator
    Paracervical Block with lidocaine

    A paracervical block will be done prior to the placement of laminaria with 1% lidocaine and sodium bicarbonate.

    Drug: Paracervical Block with lidocaine

  • Sham comparator
    Sham paracervical block

    A sham block will be done prior to the placement of laminaria using a capped needle

    Drug: Sham paracervical block

Interventions

  • DrugParacervical Block with lidocaine

    Performance of paracervical block, using 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate, prior to laminaria insertion

    Also known as: Paracervical block

  • DrugSham paracervical block

    A capped needle will be placed on the cervix prior to laminaria insertion for purposes of blinding both the participant and research staff assessing outcomes

    Also known as: Sham block; placebo

06

What researchers measure

Primary outcomes

  1. Pain After Placement of Laminaria (100 mm Visual Analog Scale)

    We asked the participant to rate her pain on a 100 mm Visual Analog Scale (VAS) immediately after laminaria was placed. The VAS is a validated measure of pain where 0=no pain and 100=worst pain ever felt.

    Time frame: Measured within 10 seconds after placement of laminaria

Secondary outcomes

  1. Satisfaction With Overall Pain Control (100 mm Visual Analog Scale)

    Patients rated their satisfaction with overall pain control on the 100 mm VAS, with 0 as not satisfied at all and 100 as completely satisfied

    Time frame: 15 minutes post-operatively

  2. Paracervical or Sham Block Pain

    Participants reported her pain level on the 100 mm Visual Analog Scale (VAS) within 10 seconds after she received either the paracervical block or the sham block. The VAS is a validated measure of pain where 0=no pain and 100=worst pain ever felt.

    Time frame: Within 10 seconds after receiving paracervical or sham block

07

Results

Posted Apr 14, 2017
Limitations and caveats
1. Overall pain scores lower than in other published studies - speaks to generalizability 2. Paracervical block formulation might not be what is commonly used elsewhere 3. 76% of participants were able to correctly guess their group allocation

Participant flow

Participants recruited from May 2015 to Dec 2015 at two of the faculty practice offices of the University of Hawaii Department of OB/gyn.

Participant flow — Overall Study
MilestoneParacervical Block With LidocaineSham Paracervical Block
Started2021
Completed2021
Not completed00

Outcome measures

PrimaryPain After Placement of Laminaria (100 mm Visual Analog Scale)

We asked the participant to rate her pain on a 100 mm Visual Analog Scale (VAS) immediately after laminaria was placed. The VAS is a validated measure of pain where 0=no pain and 100=worst pain ever felt.

Time frame:
Measured within 10 seconds after placement of laminaria
Reported as:
Median · units on a scale (100 mm VAS)
Pain After Placement of Laminaria (100 mm Visual Analog Scale)
units on a scale (100 mm VAS)Paracervical Block With LidocaineSham Paracervical Block
Pain After Placement of Laminaria (100 mm Visual Analog Scale)13 (2 to 39)54 (27 to 61)
Statistical analysis
  • Paracervical Block With Lidocaine vs Sham Paracervical Block · Wilcoxon (Mann-Whitney) · p = 0.01
SecondarySatisfaction With Overall Pain Control (100 mm Visual Analog Scale)

Patients rated their satisfaction with overall pain control on the 100 mm VAS, with 0 as not satisfied at all and 100 as completely satisfied

Time frame:
15 minutes post-operatively
Reported as:
Median · units on a scale (100 mm VAS)
Satisfaction With Overall Pain Control (100 mm Visual Analog Scale)
units on a scale (100 mm VAS)Paracervical Block GroupSham Block Group
Satisfaction With Overall Pain Control (100 mm Visual Analog Scale)95 (78 to 100)70 (44 to 90)
Statistical analysis
  • Paracervical Block Group vs Sham Block Group · Wilcoxon (Mann-Whitney) · p = 0.05
SecondaryParacervical or Sham Block Pain

Participants reported her pain level on the 100 mm Visual Analog Scale (VAS) within 10 seconds after she received either the paracervical block or the sham block. The VAS is a validated measure of pain where 0=no pain and 100=worst pain ever felt.

Time frame:
Within 10 seconds after receiving paracervical or sham block
Reported as:
Median · units on a scale (100 mm VAS)
Paracervical or Sham Block Pain
units on a scale (100 mm VAS)Paracervical Block GroupSham Block Group
Paracervical or Sham Block Pain14 (6 to 31)27 (6 to 41)
Statistical analysis
  • Paracervical Block Group vs Sham Block Group · Wilcoxon (Mann-Whitney) · p = 0.34

Adverse events

Collected over 7 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paracervical Block With Lidocaine—0/20 (0%)0/20 (0%)
Sham Paracervical Block—0/21 (0%)0/21 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Paracervical Block GroupSham Block GroupTotal
Mean25.80 ± 6.1229.81 ± 6.9227.85 ± 6.77
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Paracervical Block GroupSham Block GroupTotal
Females202141
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Paracervical Block GroupSham Block GroupTotal
White/Caucasian5712
Black/African American101
Asian5914
Native Hawaiian/Pacific Islander101020
Hispanic/Latina112
Region of Enrollment
Region of Enrollment(Participants)Paracervical Block GroupSham Block GroupTotal
United States202141
08

Study locations

1 site
  • University Women's Health Specialists
    Honolulu, Hawaii 96826, United States
09

References and documents

Publications

  • Grimes DA, Schulz KF, Cates WJ Jr. Prevention of uterine perforation during curettage abortion. JAMA. 1984 Apr 27;251(16):2108-11. PubMed 6708260 ↗
  • Renner RM, Nichols MD, Jensen JT, Li H, Edelman AB. Paracervical block for pain control in first-trimester surgical abortion: a randomized controlled trial. Obstet Gynecol. 2012 May;119(5):1030-7. doi: 10.1097/AOG.0b013e318250b13e. PubMed 22525915 ↗
  • Kan AS, Ng EH, Ho PC. The role and comparison of two techniques of paracervical block for pain relief during suction evacuation for first-trimester pregnancy termination. Contraception. 2004 Aug;70(2):159-63. doi: 10.1016/j.contraception.2004.03.013. PubMed 15288222 ↗
  • Mercier RJ, Liberty A. Intrauterine lidocaine for pain control during laminaria insertion: a randomized controlled trial. Contraception. 2014 Dec;90(6):594-600. doi: 10.1016/j.contraception.2014.07.008. Epub 2014 Jul 23. PubMed 25139724 ↗
  • Borgatta L, Roncari D, Sonalkar S, Mark A, Hou MY, Finneseth M, Vragovic O. Mifepristone vs. osmotic dilator insertion for cervical preparation prior to surgical abortion at 14-16 weeks: a randomized trial. Contraception. 2012 Nov;86(5):567-71. doi: 10.1016/j.contraception.2012.05.002. Epub 2012 Jun 6. PubMed 22682721 ↗
  • Drey EA, Benson LS, Sokoloff A, Steinauer JE, Roy G, Jackson RA. Buccal misoprostol plus laminaria for cervical preparation before dilation and evacuation at 21-23 weeks of gestation: a randomized controlled trial. Contraception. 2014 Apr;89(4):307-13. doi: 10.1016/j.contraception.2013.10.013. Epub 2013 Nov 4. PubMed 24560477 ↗
  • Goldberg AB, Drey EA, Whitaker AK, Kang MS, Meckstroth KR, Darney PD. Misoprostol compared with laminaria before early second-trimester surgical abortion: a randomized trial. Obstet Gynecol. 2005 Aug;106(2):234-41. doi: 10.1097/01.AOG.0000168629.17326.00. PubMed 16055570 ↗
  • Prairie BA, Lauria MR, Kapp N, Mackenzie T, Baker ER, George KE. Mifepristone versus laminaria: a randomized controlled trial of cervical ripening in midtrimester termination. Contraception. 2007 Nov;76(5):383-8. doi: 10.1016/j.contraception.2007.07.008. Epub 2007 Oct 4. PubMed 17963864 ↗
  • Hakim-Elahi E, Tovell HM, Burnhill MS. Complications of first-trimester abortion: a report of 170,000 cases. Obstet Gynecol. 1990 Jul;76(1):129-35. PubMed 2359559 ↗
  • Blanco LJ, Reid PR, King TM. Plasma lidocaine levels following paracervical infiltration for aspiration abortion. Obstet Gynecol. 1982 Oct;60(4):506-8. PubMed 7121936 ↗
  • Soon R, Tschann M, Salcedo J, Stevens K, Ahn HJ, Kaneshiro B. Paracervical Block for Laminaria Insertion Before Second-Trimester Abortion: A Randomized Controlled Trial. Obstet Gynecol. 2017 Aug;130(2):387-392. doi: 10.1097/AOG.0000000000002149. PubMed 28697113 ↗

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02454296
Lead sponsor
University of Hawaii
Responsible party
Reni Soon (Assistant Professor, University of Hawaii) — Principal investigator
First posted
May 27, 2015
Start date
May 2015
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
Apr 14, 2017
Last update
Apr 14, 2017

Study contacts

Principal Investigator
principal investigator · University of Hawaii

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion